Literature DB >> 1658386

Human cytomegalovirus inhibits human immunodeficiency virus replication in cells productively infected by both viruses.

V Koval1, C Clark, M Vaishnav, S A Spector, D H Spector.   

Abstract

We have been studying the role of human cytomegalovirus (HCMV) as a potential cofactor in human immunodeficiency virus (HIV)-related disease. The clinical relevance of HCMV is highlighted by the fact that it is a principal viral pathogen in patients with AIDS and is known to infect the same cells as HIV. In this study, we focused on the molecular interactions between HIV and HCMV in human fibroblasts and in the human glioblastoma/astrocytoma-derived cell line U373 MG, cells which can be productively infected by both viruses. Because these cells are CD4-, we used HIV pseudotyped with a murine amphotropic retrovirus as described previously (D. H. Spector, E. Wade, D. A. Wright, V. Koval, C. Clark, D. Jaquish, and S. A. Spector, J. Virol. 64:2298-2308, 1990). Initial studies showed that when cells were preinfected with HIV (Ampho-1B) for 5 days and then superinfected with HCMV, HIV antigen production dropped significantly in the coinfected cells but continued to rise in cells infected with HIV (Ampho-1B) alone. HCMV production, however, was unaffected by the presence of HIV. Further analysis showed that HIV steady-state RNA levels and gag and env protein production were also inhibited in the presence of HCMV. The transcriptional inhibition of HIV was particularly surprising in view of the previous results of several other laboratories as well as our own that HCMV infection stimulates HIV long terminal repeat-chloramphenicol acetyltransferase (LTR-CAT) expression in transient expression assays. To investigate this further, we transfected the HIV LTR-CAT construct into either uninfected cells or cells which had been preinfected with HIV. The cells were infected with HCMV 24 h posttransfection and assayed for CAT gene expression at 48 h after HCMV infection. Although there was some stimulation of the LTR-CAT in cells that were dually infected by HIV and HCMV, it was 16-fold less than that in the cells infected only with HCMV. This suggests that in the presence of the HIV infection, the stimulation of the HIV LTR-CAT gene by HCMV is significantly reduced. Experiments with UV-irradiated HCMV and the HCMV DNA polymerase inhibitor ganciclovir showed that HCMV transcription is necessary for the reduction in HIV production to occur; however, replication of the HCMV genome or any events which take place after DNA replication are not necessary. These results, coupled with the observation that inhibition is usually first seen between 8 and 24 h after HCMV infection, suggest that an HCMV early protein is involved in repression of HIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658386      PMCID: PMC250810     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

Authors:  J R Rusche; D L Lynn; M Robert-Guroff; A J Langlois; H K Lyerly; H Carson; K Krohn; A Ranki; R C Gallo; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS.

Authors:  D H Gabuzda; D D Ho; S M de la Monte; M S Hirsch; T R Rota; R A Sobel
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

3.  Human immunodeficiency virus pseudotypes with expanded cellular and species tropism.

Authors:  D H Spector; E Wade; D A Wright; V Koval; C Clark; D Jaquish; S A Spector
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Hepatitis B virus X gene can transactivate heterologous viral sequences.

Authors:  J S Twu; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Identification of sequence requirements and trans-acting functions necessary for regulated expression of a human cytomegalovirus early gene.

Authors:  S I Staprans; D K Rabert; D H Spector
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

6.  Suppression of human immunodeficiency virus type 1 replication by human herpesvirus-6.

Authors:  D R Carrigan; K K Knox; M A Tapper
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

7.  Differential expression in human and mouse cells of human immunodeficiency virus pseudotyped by murine retroviruses.

Authors:  B Chesebro; K Wehrly; W Maury
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Cytomegalovirus infection and trans-activation of HIV-1 and HIV-2 LTRs in human astrocytoma cells.

Authors:  H Duclos; E Elfassi; S Michelson; F Arenzana-Seisdedos; U Hazan; A Munier; J L Virelizier
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

9.  Identification of a region within the human immunodeficiency virus type 1 long terminal repeat that is essential for transactivation by the hepatitis B virus gene X.

Authors:  J S Twu; C A Rosen; W A Haseltine; W S Robinson
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

10.  Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products.

Authors:  G P Rice; R D Schrier; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

View more
  12 in total

1.  Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS.

Authors:  S A Spector; K Hsia; M Crager; M Pilcher; S Cabral; M J Stempien
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes: possible role of endogenous interleukin-8.

Authors:  M R Capobianchi; C Barresi; P Borghi; S Gessani; L Fantuzzi; F Ameglio; F Belardelli; S Papadia; F Dianzani
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 3.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

4.  Differential effects of human cytomegalovirus on integrated and unintegrated human immunodeficiency virus sequences.

Authors:  V Koval; F M Jault; P G Pal; T N Moreno; C Aiken; D Trono; S A Spector; D H Spector
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  The effects of cytomegalovirus on human immunodeficiency virus replication in brain-derived cells correlate with permissiveness of the cells for each virus.

Authors:  F M Jault; S A Spector; D H Spector
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

6.  A model system for human cytomegalovirus-mediated modulation of human immunodeficiency virus type 1 long terminal repeat activity in brain cells.

Authors:  T N Moreno; E A Fortunato; K Hsia; S A Spector; D H Spector
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection.

Authors:  S M Rodems; D H Spector
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Human cytomegalovirus replication correlates with differentiation in a hematopoietic progenitor cell line and can be modulated by HIV-1.

Authors:  T Lazzarotto; G Furlini; M C Re; E Ramazzotti; B Campisi; M P Landini
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Adenovirus vectors block human immunodeficiency virus-1 replication in human alveolar macrophages by inhibition of the long terminal repeat.

Authors:  Robert J Kaner; Francisco Santiago; Franck Rahaghi; Elizabeth Michaels; John P Moore; Ronald G Crystal
Journal:  Am J Respir Cell Mol Biol       Date:  2009-10-05       Impact factor: 6.914

10.  Interactions between human immunodeficiency virus type 1 and human cytomegalovirus in human term syncytiotrophoblast cells coinfected with both viruses.

Authors:  F D Tóth; P Mosborg-Petersen; J Kiss; G Aboagye-Mathiesen; H Hager; C B Juhl; L Gergely; M Zdravkovic; J Aranyosi; L Lampé
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.